Literature DB >> 25485876

Fibrinolysis use among patients requiring interhospital transfer for ST-segment elevation myocardial infarction care: a report from the US National Cardiovascular Data Registry.

Amit N Vora1, DaJuanicia N Holmes1, Ivan Rokos2, Matthew T Roe1, Christopher B Granger1, William J French3, Elliott Antman4, Timothy D Henry5, Laine Thomas1, Eric R Bates6, Tracy Y Wang1.   

Abstract

IMPORTANCE: Guidelines for patients with ST-segment elevation myocardial infarction (STEMI) recommend timely reperfusion with primary percutaneous coronary intervention (pPCI) or fibrinolysis. Among patients with STEMI who require interhospital transfer, it is unclear how reperfusion strategy selection and outcomes vary with interhospital drive times.
OBJECTIVE: To assess the association of estimated interhospital drive times with reperfusion strategy selection among transferred patients with STEMI in the United States. DESIGN, SETTING, AND PARTICIPANTS: We identified 22,481 patients eligible for pPCI or fibrinolysis who were transferred from 1771 STEMI referring centers to 366 STEMI receiving centers in the Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines database between July 1, 2008, and March 31, 2012. MAIN OUTCOMES AND MEASURES: In-hospital mortality and major bleeding.
RESULTS: The median estimated interhospital drive time was 57 minutes (interquartile range [IQR], 36-88 minutes). When the estimated drive time exceeded 30 minutes, only 42.6% of transfer patients treated with pPCI achieved the first door-to-balloon time within 120 minutes. Only 52.7% of eligible patients with a drive time exceeding 60 minutes received fibrinolysis. Among 15,437 patients with estimated drive times of 30 to 120 minutes who were eligible for fibrinolysis or pPCI, 5296 (34.3%) received pretransfer fibrinolysis, with a median door-to-needle time of 34 minutes (IQR, 23-53 minutes). After fibrinolysis, the median time to transfer to the STEMI receiving center was 49 minutes (IQR, 34-69 minutes), and 97.1% underwent follow-up angiography. Patients treated with fibrinolysis vs pPCI had no significant mortality difference (3.7% vs 3.9%; adjusted odds ratio, 1.13; 95% CI, 0.94-1.36) but had higher bleeding risk (10.7% vs 9.5%; adjusted odds ratio, 1.17; 95% CI, 1.02-1.33). CONCLUSIONS AND RELEVANCE: In the United States, neither fibrinolysis nor pPCI is being optimally used to achieve guideline-recommended reperfusion targets. For patients who are unlikely to receive timely pPCI, pretransfer fibrinolysis, followed by early transfer for angiography, may be a reperfusion option when potential benefits of timely reperfusion outweigh bleeding risk.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25485876     DOI: 10.1001/jamainternmed.2014.6573

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


  21 in total

Review 1.  Drug Treatment of STEMI in the Elderly: Focus on Fibrinolytic Therapy and Insights from the STREAM Trial.

Authors:  Peter R Sinnaeve; Thierry Danays; Kris Bogaerts; Frans Van de Werf; Paul W Armstrong
Journal:  Drugs Aging       Date:  2016-02       Impact factor: 3.923

2.  Acute coronary syndromes: Prehospital therapy for STEMI.

Authors:  Gregory B Lim
Journal:  Nat Rev Cardiol       Date:  2015-01-06       Impact factor: 32.419

Review 3.  Contemporary management of ST-segment elevation myocardial infarction.

Authors:  Ajay Yadlapati; Mark Gajjar; Daniel R Schimmel; Mark J Ricciardi; James D Flaherty
Journal:  Intern Emerg Med       Date:  2016-10-06       Impact factor: 3.397

Review 4.  Cardiological Society of India: Position statement for the management of ST elevation myocardial infarction in India.

Authors:  Santanu Guha; Rishi Sethi; Saumitra Ray; Vinay K Bahl; S Shanmugasundaram; Prafula Kerkar; Sivasubramanian Ramakrishnan; Rakesh Yadav; Gaurav Chaudhary; Aditya Kapoor; Ajay Mahajan; Ajay Kumar Sinha; Ajit Mullasari; Akshyaya Pradhan; Amal Kumar Banerjee; B P Singh; J Balachander; Brian Pinto; C N Manjunath; Chandrashekhar Makhale; Debabrata Roy; Dhiman Kahali; Geevar Zachariah; G S Wander; H C Kalita; H K Chopra; A Jabir; JagMohan Tharakan; Justin Paul; K Venogopal; K B Baksi; Kajal Ganguly; Kewal C Goswami; M Somasundaram; M K Chhetri; M S Hiremath; M S Ravi; Mrinal Kanti Das; N N Khanna; P B Jayagopal; P K Asokan; P K Deb; P P Mohanan; Praveen Chandra; Col R Girish; O Rabindra Nath; Rakesh Gupta; C Raghu; Sameer Dani; Sandeep Bansal; Sanjay Tyagi; Satyanarayan Routray; Satyendra Tewari; Sarat Chandra; Shishu Shankar Mishra; Sibananda Datta; S S Chaterjee; Soumitra Kumar; Soura Mookerjee; Suma M Victor; Sundeep Mishra; Thomas Alexander; Umesh Chandra Samal; Vijay Trehan
Journal:  Indian Heart J       Date:  2017-03-23

Review 5.  Use of ticagrelor alongside fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: Practical perspectives based on data from the TREAT study.

Authors:  Otavio Berwanger; Magdy Abdelhamid; Thomas Alexander; Abdulmajeed Alzubaidi; Oleg Averkov; Philip Aylward; Eduardo Contreras Zúñiga; Sigrun Halvorsen; Ricardo Iglesias; Muhamad A Sk Abdul Kader; Mohammad Zubaid; Khalid F AlHabib
Journal:  Clin Cardiol       Date:  2018-10-16       Impact factor: 2.882

6.  Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial.

Authors:  Otavio Berwanger; Jose C Nicolau; Antonio C Carvalho; Lixin Jiang; Shaun G Goodman; Stephen J Nicholls; Alexander Parkhomenko; Oleg Averkov; Carlos Tajer; Germán Malaga; Jose F K Saraiva; Francisco A Fonseca; Fábio A De Luca; Helio P Guimaraes; Pedro G M de Barros E Silva; Lucas P Damiani; Denise M Paisani; Camila M R Lasagno; Carolina T Candido; Nanci Valeis; Diogo D F Moia; Leopoldo S Piegas; Christopher B Granger; Harvey D White; Renato D Lopes
Journal:  JAMA Cardiol       Date:  2018-05-01       Impact factor: 14.676

7.  Interhospital transfer for acute surgical care: does delay matter?

Authors:  Kristy Kummerow Broman; Rachel M Hayes; Sunil Kripalani; Eduard E Vasilevskis; Sharon E Phillips; Jesse M Ehrenfeld; Michael D Holzman; Kenneth W Sharp; Richard A Pierce; William H Nealon; Benjamin K Poulose
Journal:  Am J Surg       Date:  2016-06-01       Impact factor: 2.565

8.  Indirect mitral annuloplasty: a feasible or a mirage technology.

Authors:  Carlos E Ruiz; Damián Sánchez-Quintana
Journal:  EuroIntervention       Date:  2011-05       Impact factor: 6.534

Review 9.  Percutaneous Coronary Intervention after Fibrinolysis for ST-Segment Elevation Myocardial Infarction Patients: An Updated Systematic Review and Meta-Analysis.

Authors:  Feng Liu; Qinglong Guo; Guoqiang Xie; Han Zhang; Yaxi Wu; Lixia Yang
Journal:  PLoS One       Date:  2015-11-02       Impact factor: 3.240

10.  Neighborhood and Acute Myocardial Infarction Mortality as Related to the Driving Time to Percutaneous Coronary Intervention-Capable Hospital.

Authors:  Appathurai Balamurugan; Robert Delongchamp; Lucille Im; Joseph Bates; Jawahar L Mehta
Journal:  J Am Heart Assoc       Date:  2016-02-16       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.